No Picture
Business News

Ford scrambles to restart truck production after fire at supplier

DETROIT (Reuters) – Ford Motor Co is working with a key supplier to shift some parts production from Michigan to Ontario, Canada, after a fire and subsequent parts shortages forced the automaker to halt manufacturing of its highly profitable full-size pickups, according to sources familiar with the companies’ plans.

…read more […]

No Picture
Business News

Starbucks deal gives Nestle more punch in fight with JAB

LONDON/ZURICH/LOS ANGELES (Reuters) – Nestle’s $7 billion licensing deal for Starbucks’ retail business gives it a much-needed boost in its battle against JAB, the privately owned investment firm stirring up the coffee industry with a string of deals. JAB, the family office of Europe’s billionaire Reimann clan, has built up the world’s second-largest coffee business over the past five years.

…read more […]

No Picture
Trading Ideas

Healthcare giant Novartis signed a $1.2 million contract with Michael Cohen's consulting firm, took one meeting, and realized he couldn't help them

Pharmaceutical giant Novartis is among the companies listed in paying Essential Consulting, a firm linked to Michael Cohen, President Donald Trump’s lawyer. Novartis signed a $100,000 a month contract with Cohen’s firm in February 2017. “Novartis determined that Michael Cohen and Essential Consultants would be unable to provide the services that Novartis had anticipated related to US healthcare policy matters,” the company said in a statement. …read more […]

No Picture
Trading Ideas

AstraZeneca Stock Price and Research (NYSE: AZN)

AstraZeneca (NYSE: AZN) is a large cap company that operates within the pharmaceutical industry. Its market cap is $92 billion today and the total one-year return is 24.61% for shareholders.

AstraZeneca stock is beating the market, and it reports earnings soon. But does that make it a good buy today? To answer this question we’ve turned to the Investment U Stock Grader. Our research team built this system to diagnose the financial health of a company.

Our system looks at six key metrics…

[iu-adbox]

✗ Earnings-per-Share (EPS) Growth: AstraZeneca reported a recent EPS growth rate of -29.45%. That’s below the pharmaceutical industry average …read more […]